about
Drugs for type 2 diabetes: role in the regulation of bone metabolismCardiovascular effects of basal insulinsThe therapy of insulin resistance in other diseases besides type 2 diabetesBone: incretin hormones perceiver or receiver?Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels.Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetesGlucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.Adipokines as possible new predictors of cardiovascular diseases: a case control study.Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trialsEffects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.Is glucose control important for prevention of cardiovascular disease in diabetes?From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Incretin-based therapies and cardiovascular risk.Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis.Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells.[Overview of cardiovascular risk factors in diabetic patients: focus on hypoglycemia, dyslipidemia, body weight and cardiovascular disease].Association between oral isotretinoin therapy and unmasked latent immuno-mediated diabetes.Orlistat and sibutramine beyond weight loss.Lipids seasonal variability in type 2 diabetes.Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study.Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.Is there a practical way of predicting therapeutic success in type 2 diabetes on the basis of psychological features? Development and validation of the Psychological Predictors of Therapeutic success in Diabetes (PPTD) questionnaire.Lipid levels in obese and nonobese subjects as predictors of fasting and postload glucose metabolism.Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance.Psychopathology and continuous subcutaneous insulin infusion in type 1 diabetes
P50
Q26775763-F7D6AA7D-0ACA-40D8-8665-00A52A13F6C7Q26800249-F514F533-A486-47F3-8466-6AACFCC4B321Q26822399-7F0EA559-AF8C-42BD-A7C4-3CF183BBB70BQ27008949-B2B42AC2-594F-4151-BF58-33D6CB113538Q30248634-D3298118-8270-46EF-AA8E-AF82BD1B57C2Q33602347-E83D4F77-7EE2-437B-A8FC-8F990911D657Q34341759-F3FA5B52-29D0-488D-876A-609FB38571FDQ34401433-19363E9C-AB5E-428F-8E4D-7DBBBCD63769Q34421989-0FFDE6E8-060E-493C-84BB-9C5CA2425DCDQ34569672-493F7A44-23F1-4968-B58B-7301205E4ACDQ34633860-A0A73F4D-06B9-40DB-A220-C98F1609F53FQ35176565-B0638916-0036-4047-A320-8F678B9D6C89Q35408148-BE180EC1-C818-4534-8459-8F27AE42234BQ35996636-6BB72580-97BC-4851-A417-AFD01DE5E43FQ36073461-A824E6F0-3B96-4F8F-803C-920D4E131D5EQ36159201-C59E84C3-9ED4-493A-B4B0-6A519303C7B6Q37577137-2F55CF27-4D99-48FA-9B50-6E957250215EQ37900151-75785AC8-0229-451E-AC6E-6F6080F8AADCQ37996083-6A507E2A-42E9-47FD-9518-9CAA9267D9B1Q38202019-D8B60A7B-125C-47BF-864E-2E3C3B3A9178Q39705884-B3C37329-2098-4AE0-8FBA-3AD4AC00FAB4Q43555886-03D7AB48-FDC9-43D3-94A5-005E4DF406B5Q45917399-0B6F54EF-5D52-4B8F-8F90-DC760F94B222Q46956998-E919C7BD-E6A1-4048-AC50-9D4B5552E3F5Q47613748-6AE9C859-B46D-433E-9D38-D27E3D8A768DQ47986455-63836C8D-7F9E-45A3-AC29-329750B69865Q48317531-EDFB02DF-BDA9-4A96-AFF9-32E8C790D8BCQ48326547-476C14A9-C1DE-4118-9730-DC33A0D63CD5Q48339050-2688F4AD-CE1A-46B3-94F7-928298139364Q48372707-6C637CDA-7BA8-4013-8ED6-2185310330C5Q51360179-C6A637DD-F6AC-4E30-99A9-5ABB72DD4960Q51366807-265087BA-405D-4251-B79B-9CC74A90D326Q59034125-13949B16-A982-46F0-B427-464709181B26
P50
name
Ilaria Dicembrini
@ast
Ilaria Dicembrini
@en
Ilaria Dicembrini
@es
Ilaria Dicembrini
@nl
type
label
Ilaria Dicembrini
@ast
Ilaria Dicembrini
@en
Ilaria Dicembrini
@es
Ilaria Dicembrini
@nl
prefLabel
Ilaria Dicembrini
@ast
Ilaria Dicembrini
@en
Ilaria Dicembrini
@es
Ilaria Dicembrini
@nl